中文

康芝药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.10B-14.1%
Gross profit¥0.06B
Operating income¥-0.01B
Net income¥-0.01B
Gross margin60.6%Net margin -12.6%
Revenue Q/Q-30.9%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.04B39.4%
R&D¥0.00B3.7%
SG&A¥0.06B58.4%
Tax & other¥0.01B5.9%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

ST荃银长信科技*ST金灵科新机电金刚光伏国联水产华伍股份ST易联众智云股份高新兴尤洛卡双林股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies